BioLineRx Ltd.
BioLineRx Ltd. (BLRX) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
blrx · stock forecast · 7 analysts (3M) · FMP · updated Jun 8, 2026
Analyst Rating & Consensus
Based on 7 Wall Street analysts in the past 3 months
Buy
7 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$0.00
Consensus
$0.00
+0.0% upside
Low
$0.00
Median: $0 · Last Close: $3.12
Short-Term Price Prediction
Algorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $3.20 | ↑ 2.58% |
1-day model range: $3.16–$3.24. Peak: $3.24 (+2.58%).
Long-Term Stock Price Prediction
Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031
| Year | Avg Price | Change |
|---|---|---|
| 2027 | $2 | -50.0% |
| 2028 | $1 | -62.5% |
| 2029 | $1 | -67.2% |
| 2030 | $1 | -69.2% |
| 2031 | — | -70.2% |
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
NEUTRAL
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · BLRX · Jun 8, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2025-06-17 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-05-30 | Jones Trading | Upgrade ↑ | Hold→Buy |
| 2025-05-28 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-04-02 | Jones Trading | Downgrade ↓ | Buy→Hold |
| 2025-03-31 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-11-25 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-11-06 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-06-03 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-05-29 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-04-17 | HC Wainwright & Co. | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on BioLineRx Ltd. (BLRX) stock. Of the recent 29 rating actions, 3 were upgrades and 3 were downgrades. 7 analysts currently cover BLRX.
Analyst Recommendation Trends
BLRX analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 1 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$2M
↓ 69.2% YoY
Revenue Next Year
$2M
↑ 12.6% YoY
EPS This Year
$-0.47
EPS Next Year
$-0.32
↓ 31.2% YoY
EPS ForecastReported vs Estimated
Analysts forecast BLRX EPS of $-0.47 for the current fiscal year, based on estimates from 1 analysts. The BLRX revenue forecast is $2M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The BLRX stock forecast is supported by two independent data sources: analyst consensus ratings from 7 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus BLRX price target is $0.00 (+0.0% upside), with an analyst consensus of Buy.
The BLRX short-term stock prediction for tomorrow is $3.20 (+2.58%). The BLRX stock price prediction for 2027 estimates an average of $2. The BLRX stock prediction for 2030 projects a range of $1–$1.
BioLineRx Ltd. trades on NASDAQ under the ticker BLRX. The BLRX stock outlook for 2027 is broadly positive, supported by a Buy consensus among 100% of covering analysts.
Frequently asked questions
BLRX forecast · 8 questionsAccording to 7 Wall Street analysts, the average 12-month BLRX price target is $0.00, with a high forecast of $0.00 and a low of $0.00. The median price target is shown in the chart above when available. This implies +0.0% potential upside from the current price of $3.12.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.